Tag: Immutep Limited
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Smarter energy decisions: GridBeyond unveils AI-powered Bid Optimiser in Australia
As Australia’s energy transition accelerates, businesses participating in the National Electricity Market (NEM) are facing growing challenges in managing their energy assets efficiently.
